Moleculin Biotech Total Assets 2011-2026 | MBRX

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Moleculin Biotech

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
22.1 M	16.9 M	38.2 M	57.4 M	84.1 M	29 M	25.2 M	19.6 M	19.5 M	16.4 M	28.1 K	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
84.1 M	28.1 K	29.9 M

Quarterly Total Assets Moleculin Biotech

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
20.4 M	21.6 M	21 M	16.9 M	23.4 M	25.6 M	-	38.2 M	39.5 M	47.1 M	51.1 M	57.4 M	65.4 M	73.3 M	78.8 M	84.1 M	88.7 M	93.5 M	99.8 M	29 M	29 M	29 M	29 M	25.2 M	25.2 M	25.2 M	25.2 M	19.6 M	19.6 M	19.6 M	19.6 M	19.5 M	19.5 M	19.5 M	19.5 M	16.4 M	16.4 M	16.4 M	16.4 M	28.1 K	28.1 K	28.1 K	28.1 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
99.8 M	28.1 K	33 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
ARCA biopharma ABIO	396 M	-	1052.0 %	$ 415 M	USA
Verastem VSTM	246 M	$ 5.04	-4.73 %	$ 349 M	USA
Voyager Therapeutics VYGR	252 M	$ 3.96	-4.12 %	$ 232 M	USA
VistaGen Therapeutics VTGN	84.3 M	$ 0.57	-5.87 %	$ 17.6 M	USA
Aeterna Zentaris AEZS	35.1 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	6.95 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
AIkido Pharma AIKI	47.1 M	-	1.93 %	$ 17.4 M	USA
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	151 M	-	2.54 %	$ 160 B	France
Albireo Pharma ALBO	302 M	-	-0.23 %	$ 916 M	USA
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Aileron Therapeutics ALRN	24.2 M	-	10.36 %	$ 9.8 M	USA
Aptinyx APTX	66.7 M	-	-39.0 %	$ 4.57 M	USA
Midatech Pharma plc MTP	14.8 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Arena Pharmaceuticals ARNA	785 M	-	-6.81 %	$ 3.04 B	USA
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
Avenue Therapeutics ATXI	2.67 M	-	-52.27 %	$ 4.45 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Atreca BCEL	155 M	-	-11.76 %	$ 5.79 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
bluebird bio BLUE	619 M	-	-	$ 546 M	USA
Acasti Pharma ACST	72 M	-	4.01 %	$ 150 M	Canada
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
Avid Bioservices CDMO	337 M	-	-	$ 789 M	USA
Adverum Biotechnologies ADVM	180 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	11.6 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Adaptive Biotechnologies Corporation ADPT	513 M	$ 12.41	-11.1 %	$ 1.88 B	USA
Wave Life Sciences Ltd. WVE	638 M	$ 6.37	2.66 %	$ 1.07 B	Singapore
Xenetic Biosciences XBIO	8.36 M	$ 2.72	-2.86 %	$ 4.63 M	USA
XBiotech XBIT	150 M	$ 2.27	-1.73 %	$ 69.2 M	USA
Xenon Pharmaceuticals XENE	798 M	$ 54.48	-1.89 %	$ 4.24 B	Canada
Xeris Pharmaceuticals XERS	384 M	$ 5.4	-3.05 %	$ 866 M	USA
X4 Pharmaceuticals XFOR	290 M	$ 4.04	-6.26 %	$ 171 M	USA
Xencor XNCR	875 M	$ 11.42	-7.23 %	$ 848 M	USA
XOMA Corporation XOMA	273 M	$ 30.17	-1.18 %	$ 364 M	USA
BeiGene, Ltd. BGNE	8.19 B	-	0.49 %	$ 251 B	Cayman-islands
22nd Century Group XXII	27 M	$ 2.41	-18.03 %	$ 444 K	USA
BioDelivery Sciences International BDSI	325 M	-	-4.8 %	$ 255 M	USA
Cara Therapeutics CARA	126 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	426 M	-	-	$ 3.74 B	USA
Zai Lab Limited ZLAB	1.17 B	$ 18.0	2.8 %	$ 19.7 B	China
Enlivex Therapeutics Ltd. ENLV	27.7 M	$ 1.05	-3.67 %	$ 21.5 M	Israel
Enochian Biosciences ENOB	8.23 M	-	-	$ 40.5 M	USA